Cubicin Patent Axing Doesn't Warrant Review, Justices Told
Hospira has urged the U.S. Supreme Court not to review the invalidation of the asserted claims of four patents for Cubist Pharmaceutical's blockbuster antibiotic Cubicin, arguing that the Federal Circuit followed...To view the full article, register now.
Already a subscriber? Click here to view full article